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Todd R. Schachtman, Dissertation Supervisor 
ABSTRACT 
 
 Alzheimer’s disease is a progressive neurodegenerative disorder that results in 
synaptic and neuronal loss in regions of the brain responsible for memory and cognition.  
To date, transgenic animal models have played a crucial role in our understanding of the 
underlying mechanisms of the disease.  In the present studies, behavioral performance 
was assessed in two strains of transgenic rats that overexpress human beta amyloid 
precursor protein.  After behavioral deficits were established, females were used to assess 
the effect of estrogen deficiency on these deficits.  Previous research suggests an 
increased vulnerability for females to Alzheimer disease-like pathology; while the 
underlying causes for this are unclear, it has been suggested that estrogens have 
numerous neuroprotective effects and that the loss of estrogens during aging and 
menopause may accelerate disease-like pathology.  Both types of transgenic rats showed 
behavioral deficits compared to age-matched non-transgenic control rats and estrogen 
deficiency exacerbated behavioral symptoms reflective of Alzheimer’s disease. 
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INTRODUCTION 
 
 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 
regions of the brain responsible for memory and cognition (Alzheimer, 1987 reprinted 
from 1907; Ballard & Walker, 1999).  AD affects more than 5.4 million people in the 
United States (Reitz, 2012) and an estimated 35.6 million people worldwide (Wimo et al., 
2013).  The prevalence of AD is expected to rise with the anticipated increase in 
population life expectancy (Hebert, Scherr, Bienias, Bennett, & Evans, 2003). 
 AD is a growing public-health concern as there are currently no known cures to 
treat the disease (Reitz, 2012).  Current pharmacological interventions for AD are 
effective at treating the symptoms of the disease, but they offer no ability to prevent or 
delay neurodegeneration.  One hopeful approach to address neurodegeneration is to 
develop an appropriate animal model of the disease and to use it to test the efficacy of 
emerging therapies.  Animal models mimic aspects of the disorder, including the 
pathological, physiological, or behavioral symptoms of the human disease (Sabbagh, 
Kinney, & Cummings, 2013 2013).  The ideal model should mimic multiple aspects of 
the disease, including its etiology and a time-dependent progression of the pathology; it 
should also involve similar structures to that of the human pathology (Do Carmo & 
Cuello, 2013).  One reason for the lack of progress towards developing a cure is that there 
are currently no animal models that completely capture the full spectrum of AD 
pathology.  This introduction briefly summarizes the most successful mouse models and 
addresses the development of a new rat model to study AD, with a focus on elucidating 
the link between gender and AD.  
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Female Gender as a Risk Factor for AD 
 Although age is the most significant risk factor for the development of AD, age-
related loss of sex steroid hormones is also an established risk factor in both men and 
women (Li & Singh, 2014; Pike, Carroll, Rosario, & Barron, 2009 & Barron, 2009; Vest 
& Pike, 2013).  While the relationships between sex steroid hormones and AD are not 
fully understood, findings from both human and animal studies show that depletion of 
estrogen and progesterone in women and androgens in men increase the vulnerability of 
the aging brain to AD pathogenesis (Vest & Pike, 2013).  Apart from declining levels of 
circulating sex steroid hormones, female gender may also be an inherent risk factor for 
AD.  Nearly two-thirds of patients with AD are women (Gao, Hendrie, Hall, & Hui, 
1998; Hebert, Weuve, Scherr, & Evans, 2013).  Not only is there is a higher number of 
female patients with AD than male patients with AD (Andersen et al., 1999; Bachman et 
al., 1992; Brayne et al., 1995; Brookmeyer, Gray, & Kawas, 1998; Farrer et al., 1997), 
but the incidence, which refers to the number of new cases within a certain time period, 
of AD is also higher in women (Andersen et al., 1999; Jorm & Jolley, 1998; Miech et al., 
2002; Ruitenberg, Ott, van Swieten, Hofman, & Breteler, 2001; Hofman, & Breteler, 
2001).  However, these differences in the prevalence and incidence rates of AD are 
difficult to interpret due to gender differences in life expectancy.  Nonetheless, AD 
pathology and AD-related cognitive decline are greater in women than in men (Barnes et 
al., 2005; Buckwalter, Sobel, Dunn, Diz, & Henderson, 1993; Corder et al., 2004; 
Henderson & Buckwalter, 1994; Read et al., 2006; Ruitenberg et al., 2001; Sinforiani et 
al., 2010; Swaab, Chung, Kruijver, Hofman, & Ishunina, 2001).  Furthermore, women 
with AD tend to have relatively greater difficulty with cognitive skills that are viewed as 
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female-advantaged, such as verbal fluency, naming, and verbal episodic memory 
(Henderson & Buckwalter, 1994; Ripich, Petrill, Whitehouse, & Zoil, 1995). 
 It has been suggested that women may be disproportionately affected by some 
genetic and environmental risk factors.  For example, there is a stronger association of 
sporadic AD with the apolopoprotein E ε4 allele, a major genetic risk factor for AD, in 
women than in men.  This association correlates with memory impairments and greater 
hippocampal and cortical atrophy (Altmann, Tian, Henderson, Greicius, & Alzheimer's 
Disease Neuroimaging Initiative, 2014; Damoiseaux, Prater, Miller, & Greicius, 2012; 
Farrer et al., 1997; Fleisher et al.; Liu et al., 2010; Payami et al., 1994), as well as higher 
amyloid plaque and neurofibrillary tangle burden in the brains of women than of men 
who are carriers of the ε4 allele (Corder et al., 2004).  While the underlying causes for the 
increased vulnerability for females to AD-like pathology are unclear, Grimm, Mensah-
Nyagan, and Eckert (2016) argue that there is a close relationship between age-related 
decreases in steroid levels and the age-related increases in oxidative stress.  
Mitochondrial dysfunction is suggested to underlie these deficits in brain metabolism 
(Long, He, Shen & Li, 2012; Nilsen, 2008; Viña & Lloret, 2010).  Hence, because the 
loss of estrogens is most drastic during menopause, women may have a higher 
vulnerability to oxidative stress at this period of time, which can promote the onset of 
neurodegenerative disorders.  Overall, research suggests that estrogens have numerous 
neuroprotective effects relevant to the prevention of AD and that the loss of estrogens in 
females during aging and the menopausal period may accelerate AD-like pathology (Pike 
et al., 2009). 
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Characteristics of Transgenic Mouse Models of AD 
 To date, the most successful and widely used animal models of AD have been 
transgenic (Tg) mice.  Tg mouse models have played a crucial role in our understanding 
of the genetics underlying the disease.  All Tg models exhibit one or more of the four 
physiological symptoms of the disorder seen in humans:  (1) Senile amyloid plaques 
caused by extracellular deposits of amyloid-β peptides (Aβ), (2) intracellular deposits of 
abnormally hyperphosphorylated tau protein in the form of neurofibrillary tangles, (3) 
chronic neuroinflammation, and (4) widespread neuronal loss (Dickson & Vickers, 2001; 
Selkoe, 2001).  Tg models mimic AD by overexpressing genes that have been associated 
with the familial form of the disease.  For instance, mutations in the amyloid precursor 
protein gene (APP) on chromosome 21, the presenlin-1 gene (PS1) on chromosome 14, 
and the presenilin-2 gene (PS2) on chromosome 1, cause early-onset autosomal dominant 
AD (St George-Hyslop, 2000); and thus, Tg reproduction of AD pathology is based on 
the overexpression or transfection of mutant forms of these genes.   
 Historically, mice have been preferred as an animal model in this line of research 
mainly because the tools for mouse genome manipulation are widely available (Abbott, 
2004; Tesson et al., 2005).  Initial Tg mouse lines carried mutations of APP, thus the vast 
majority of Tg animal models of AD exhibit a massive and often rapid production and 
accumulation of Aβ peptides (Games et al., 1995; Hsiao et al., 1996; Kokjohn & Roher, 
2009).  Subsequent models have relied on PS mutations (Duff et al., 1996), tau mutations 
(Lewis et al., 2000), or a combination of two or three mutations (Holcomb et al., 1998; 
Lewis et al., 2001; Oddo et al., 2003).  In general, mouse models bearing APP and/or PS 
mutations have provided valuable information about the mechanisms involved in AD and 
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the role of Aβ pathology (Sabbagh et al., 2013).  A brief history of AD animal model 
research involving behavior is reviewed below. 
 
Behavioral Markers of AD 
 Behavioral deficits in AD are caused by progressive synaptic and neuronal loss, 
especially in the temporal and parietal regions of the brain.  One of the earliest brain 
regions affected in AD is the hippocampus, and as expected, impaired performance is 
observed on many hippocampal-dependent tasks, especially spatial learning and memory 
tasks.  Hippocampal-dependent spatial navigation is highly conserved across mammalian 
species (Squire, 1992) and navigational ability is often assessed using mazes in rodents.  
Consistent with the AD phenotype, research using Tg mice has consistently demonstrated 
AD-related impairments on a variety of spatial learning measures, including the Morris 
water maze (Blázquez, Cañete, Tobeña, Giménez-Llort, & Fernández-Teruel, 2014; 
Cañete, Blázquez, Tobeña, Giménez-Llort, & Fernández-Teruel, 2015), radial arm maze 
(Stepanichev et al., 2004; Stewart, Cacucci, & Lever, 2011; Wright et al., 2013) and the 
Barnes maze (Attar et al., 2013; Stover, Campbell, Van Winssen, & Brown, 2015; 
Walker et al., 2011; Walker et al., 2015).  The Morris water maze (MWM) is a 
hippocampal-dependent spatial learning and memory task that does not rely on appetitive 
motivation (Morris, 1984), which makes it particularly well-suited to investigate learning 
in animal models of AD (Billings, Green, McGaugh, & LaFerla, 2007; Hsiao et al., 1996; 
Kinney, Starosta, & Crawley, 2003).  Similar to the MWM, the Barnes maze is also a 
hippocampal-dependent spatial learning task, but is considered to be less stressful as it 
does not involve the stress of forced swimming (Barnes, 1979; Rosenfeld & Ferguson, 
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2014).  As such, this maze can be used with aged animals that sometimes develop 
locomotor difficulties.  Tests assessing contextual memory are also widely used to 
measure hippocampal function (Dineley, Xia, Bui, Sweatt, & Zheng, 2002).  Other tasks, 
such as the radial arm maze, novel object recognition, and passive avoidance are also 
useful in examining cognitive deficits consistent with AD in rodents.  Several 
comprehensive overviews of the literature on memory and spatial learning deficits in Tg 
mouse models have been published (Ashe, 2001; Foley, Ammar, Lee, & Mitchell, 2015; 
Kobayashi & Chen, 2005; Webster, Bachstetter, Nelson, Schmitt, & Van Eldik, 2014).   
 
Issues with Tg Mouse Models of AD 
 As mentioned, many mouse models of AD have been created, but none of them 
fully replicate the extensive cellular, biochemical, and behavioral pathology of AD 
patients (Kokjohn & Roher, 2009; Sabbagh et al., 2013).  For example, many of the Tg 
APP mouse models fail to develop neurofibrillary tangles (Colton et al., 2008; Oddo et 
al., 2003; Padmanabhan, Levy, Dickson, & Potter, 2006; Wilcock et al., 2008).  On the 
other hand, Tg mice with altered tau expression that develop AD-like tangles and cellular 
loss do not develop Aβ deposition (Sabbagh et al., 2013).  Although more sophisticated 
double and triple Tg mouse models have provided insights into the interactions between 
Aβ and tau pathologies (Mastrangelo & Bowers, 2008; Oddo et al., 2003; Sabbagh et al., 
2013; Stover et al., 2015; Wilcock, 2010), many still have drawbacks.  In humans, for 
instance, high levels of neuronal Aβ can be present for some time, sometimes decades, 
before the appearance of any cognitive symptoms (Bateman et al., 2012; Price & Morris, 
1999).  This increased Aβ load does not lead to pathology until there is an additional 
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disturbance like stroke, hypertension, or type 2 diabetes.  Not surprisingly, multiple 
pathologies appear to reduce the threshold at which AD changes are clinically manifest as 
cognitive impairment (Schneider, Arvanitakis, Bang, & Bennett, 2007).  In contrast to 
human AD, most mouse models exhibit behavioral deficits before they develop 
significant plaque pathology (Beauquis, Vinuesa, Pomilio, Pavía, & Saravia, 2014; 
Eriksen & Janus, 2007; Games, Buttini, Kobayashi, Schenk, & Seubert, 2006; Sterniczuk, 
Antle, Laferla, & Dyck, 2010; Wright et al., 2013), which fails to accurately mimic the 
disease course of human AD.  To further complicate the issue, there is evidence that 
neither plaques nor tangles are the proximate cause of neuronal dysfunction; instead, they 
may reflect the fundamental processes that accelerate synapse loss and eventually lead to 
neuronal death.  In fact, Aβ load often does not correlate with cognitive impairment 
(Arriagada, Growdon, Hedley-Whyte, & Hyman, 1992; Berg, McKeel, Miller, Baty, & 
Morris, 1993; Foley et al., 2015); instead, cognitive impairment is more strongly related 
to excessive synapse loss (Terry, 2006), an AD pathology many current mouse models 
(e.g., PDAPP, Tg2576) lack despite having extensive amyloid deposition (Irizary et al., 
1997; Irizarry, Soriano, & McNamara, 1997).  It seems as though neuronal loss can be 
induced in mice only by the combination of multiple mutations that individually are 
sufficient to cause the disease in humans (Casas et al., 2004; Schmitz et al., 2004; Oakley 
et al., 2006).   
 Even more importantly, however, cognitive deficits in Tg mice tend to be mild 
and resemble the cognitive deficits of prodromal, or early stage, AD more than of AD 
dementia.  Additionally, cognitive assessment in mice can be quite challenging.  Learning 
is slow in mice (Abbott, 2004) and their behavior is often variable and thus, may not 
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always be indicative of their true abilities.  Behavioral performance underlies cognitive 
assessment in animals, and the fact that performance does not always reflect acquired 
knowledge makes it difficult to accurately determine the effects of interventions on 
cognition, a major objective of this field of research. 
 
Rationale 
 The failure of mouse models to capture all the major features of the disorder 
highlights the necessity to develop superior models of the AD pathology.  Now that 
genome manipulation technologies have been developed for non-mouse species, it may 
be time to consider other animals as possible models of the disease, which may allow for 
new evidence regarding underlying pathology.   
 Similar to Tg mouse models, Tg rat models are also based on the overexpression 
or transfection of mutant APP and PS1 genes.  Moreover, rat models offer numerous 
advantages over mouse models.  Rats are physiologically, genetically, and 
morphologically more similar to humans than mice (Gibbs et al., 2004; Jacob & Kwitek, 
2002; Lin, 1995; Yang et al., 2004).  Additionally, rats’ larger bodies and brain size 
facilitate many experimental procedures including neurosurgery and neuroimaging 
(Tesson et al., 2005).  More importantly, rat behavior is far better characterized.  Rats 
have finer and more accurate motor coordination than mice and exhibit more complex 
learning and social behaviors (Do Carmo & Cuello, 2013; Iannaccone & Jacob, 2009).  
Consequently, rat models of AD allow for a more innovative and accurate assessment of 
the impact of pathology and novel therapies on cognition and behavior.  As a result, rats 
are increasingly being used to mimic neurodegenerative pathologies including 
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Parkinson’s (Inden et al., 2011; Nuber et al., 2013; Taravini et al., 2011), Huntington’s 
(von Hörsten et al., 2003), and even AD (Do Carmo & Cuello, 2013).  However, 
although rat models may more accurately generate the physiological characteristics of 
AD, an open question in the published literature is whether Tg rat models will also 
display the appropriate behavioral deficits of AD.   
 
Current Rat Models 
  In an attempt to generate a more accurate model of AD, Agca and colleagues 
(2008) have created a novel line of Tg rats that overexpress human APP with Swedish 
and Indiana mutations, which are genetic variations that have been linked to cause early 
onset AD in humans.  Similar to human AD, this Tg line does not always develop 
significant pathology unless there is an additional disturbance (Rosen et al., 2012).  To 
this extent, although this Tg line produces high levels of neuronal APP, it fails to produce 
Aβ plaques.  In order to increase AD pathogenesis to more accurately model human AD, 
the APP line was used to generate a double Tg line that overexpresses both the APP as 
well as the PS1 transgene.  To characterize these new rat models’ behavioral resemblance 
to AD pathology, both models of Tg rats underwent behavioral assessment in the present 
series of experiments.  Once characterized, these models were used to further investigate 
the interaction of gender and AD. 
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EXPERIMENT 1 
 
The purpose of Experiment 1 was to examine the spatial learning and memory 
deficits and anxiety levels associative with two novel rat models of AD.  To assess spatial 
learning and memory, the Barnes maze was used (Barnes, 1979).  This maze takes 
advantage of rodents’ natural aversion to bright open spaces and tendency to spend more 
time in darker enclosed areas.  More specifically, animals escape from a mildly aversive 
brightly lit circular platform surface to a small, dark recessed chamber located under one 
of 20 holes around the perimeter of the platform.  Latency to locate the escape chamber is 
measured on each trial during each testing session.  The Barnes maze procedure is able to 
tap into three distinct aspects of spatial learning and memory.  First, animals must learn 
the initial location of escape box and improved performance with each trial is indicative 
of normal learning and memory.  After learning the initial location of the escape 
chamber, the animals can be given a retention interval after which memory for the 
location can again be measured.  Lastly, the animals can also be given reversal training in 
which the location of the escape chamber is moved and the rate of learning of the new 
location can again be measured.   
The Barnes maze is a hippocampal-dependent task that been shown to be sensitive 
to both hippocampal damage and to cognitive decline in AD rodents.  Previous research 
shows that Tg animals display poor spatial learning in the Barnes maze task compared to 
their wild-type littermates in a variety of AD mouse models, including TgCRND8 
(Walker et al., 2011), 3xTg (Attar et al., 2013), and APPswe/PS1ΔE9 (O'Leary & Brown, 
2009; Reiserer, Harrison, Syverud, & McDonald, 2007).  Although very few studies have 
investigated sex differences in cognitively normal rats in the Barnes maze, findings 
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suggest no sex differences in performance on this task (Bucci, Chiba, & Gallagher, 
1995).  However, there is evidence that sex hormone levels can influence spatial learning 
performance, such that females perform better during proestrus when estrogen levels are 
high (Warren & Juraska, 1997).  Nonetheless, Tg female mice are reported to show 
poorer behavioral performance than Tg males (Carroll et al., 2010; Clinton et al., 2007; 
King et al., 1999; Pistell, Zhu, & Ingram, 2008).  Furthermore, Tg mouse models of AD 
also exhibit sex differences in AD-like neuropathology; most commonly, female mice 
show earlier and more robust Aβ accumulation than males (Andersen et al., 1999; 
Callahan et al., 2001; Carroll et al., 2010; Halford & Russell, 2009; Hirata-Fukae et al., 
2008; Lee, Cole, Palmiter, Suh, & Koh, 2002; Sturchler-Pierrat & Staufenbiel, 2000).  
The observance of greater behavioral impairment and pathology in females across 
multiple Tg mouse models suggest that females are inherently more vulnerable than 
males to AD pathogenesis (Vest & Pike, 2013).  Thus, in line with previous research, it 
was predicted that both AD rat models (APP and APP+PS1) would show spatial learning 
and memory deficits compared to age-matched non-Tg (nTg) controls, and that double 
Tg (APP+PS1) rats would show the most severe impairments.  Additionally, it was 
predicted that larger memory impairments would be observed in the female Tg rats 
compared to the male Tg rats. 
A speed-accuracy trade off in Barnes maze performance is one potential problem 
that can be difficult to control.  Animals that are presumably anxious may complete the 
task more quickly (enter the escape box) but make a larger number of errors while doing 
so.  To check whether such a speed-accuracy trade off occurs in the Barnes maze 
behavioral data, an additional test, the elevated plus maze, was administered as a measure 
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to assess anxiety levels (Handley & Mithani, 1984; Pellow, Chopin, File, & Briley, 1985; 
Walf & Frye, 2007).  This commonly used task consists of two enclosed arms and two 
open arms arranged in the shape of a plus.  Similar to the Barnes maze, the elevated plus 
maze also takes advantage of rodents’ natural aversion to open spaces and animals that 
spend less time in the open arms relative to the enclosed arms are said to have higher 
levels of anxiety.  The anxiety test was exploratory in nature and no predictions were 
made because the literature on anxiety disturbances in Tg mice has been mixed.  For 
example, many studies have found evidence for increased anxiety-like behaviors and 
hyperactivity in Tg animals (Beauquis et al., 2014; Blázquez et al., 2014; Pietropaolo, 
Feldon, & Yee, 2014; Sterniczuk et al., 2010), while others have found evidence for 
anxiolytic-like behaviors (Lok et al., 2013) and reduced exploratory behavior (Hsiao et 
al., 1995; Moechars et al., 1999).  Several reviews of similar findings have been 
published (Ashe, 2001; Webster et al., 2014).  Although the relationship between anxiety 
levels and AD is not entirely clear, this behavioral assessment was included to ensure that 
any observed spatial learning and memory performance differences were not caused by 
differences in anxiety levels given the aversive motivational nature of the Barnes maze. 
 
Materials and Methods 
 
Animals.  Male and female APP+PS1 (n = 12), APP (n = 11), and nTg Fischer 
344 (n = 12) rats aged between 8 and 12.5 months (mean = 9.8) were used (see Table 1).  
Tg rats were bred as previously described (Agca et al., 2008) and Fischer 344 controls 
were bred from parents that were obtained from Harlan (Indianapolis, IN, USA).  All 
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procedures were performed in accordance with the University of Missouri's Animal Care 
and Use Committee (ACUC) guidelines and the ILAR Guide for the Care and Use of 
Laboratory Animals.  The rats were housed in pairs in conventional cages at 20–25°C in 
a controlled lighting environment and provided ad libitum access to water and standard 
pelleted rodent chow.   
 
 Gender 
Number of Males Number of Females 
G
en
ot
yp
e APP+PS1 n = 6 n = 6 
APP n = 6 n = 5 
nTg (CTL) n = 6 n = 6 
 
Table 1.  Rats used in Experiment 1.  A total of 35 rats were used. 
 
Behavioral Assessment.  Each rat was handled at least four times prior to 
behavioral treatments to reduce anxiety due to handling during testing.  On each day that 
behavioral testing occurred, rats were transported to the testing room from the colony 
room in their home cages and acclimated in the testing room for a minimum of 30 min 
prior to the first trial.  All animals were examined in the Barnes maze first, followed by 
the elevated plus maze. 
 
Barnes Maze.  The maze consists of a grey circular platform 122 cm in diameter, 
surrounded by a wall that was 30.5 cm in height.  The maze was elevated 83.8 cm above 
the floor by a stand.  Twenty holes measuring 10.2 cm in diameter were evenly spaced 
around the perimeter.  A rectangular grey escape box (28 cm in length x 12.7 cm wide x 
   
	
14 
7.6 cm deep at the area closest to the floor of the maze tapering to 16.5 cm deep) could be 
placed beneath any hole.  The escape box included an entry ramp that provided easy entry 
access for the rat.  A black curtain was hung around the maze to surrounded the apparatus 
and ensure that rats only used the visual cues provided in the maze, instead of distal cues 
within the testing room, to navigate around the maze.  Proximal cues were more likely to 
remain constant, within subjects and across subjects, during the course of training.  Four 
visual cues consisting of various shapes (triangle, square, circle, cross) were placed at 
evenly spaced intervals on the inside of the maze walls.  Two 86-W, 120-V floodlights 
producing 1690 lumins were hung above the platform to brightly light the maze in order 
to create a potentially aversive environment to help motivate the rats to escape from the 
brightly lit, open surface in favor of the dark environment of the escape box.  One light 
was hung 68.5 on side of the maze, while the other was hung 137 cm from the other side. 
Each rat was assigned an escape hole; assigned holes were alternated across rats 
to eliminate odor cues for consecutively tested rats.  The escape box location remained 
constant for any individual rat across test trials.  Behavioral testing consisted of 2 shaping 
trials (2 trials/day) and 6 acquisition trials (2 trials/day) over a period of 3 days.  Shaping 
trials were performed exactly like the acquisition trials except that the data were not used 
in the statistical analysis.  Before shaping trials, each rat was pre-exposed to the goal box 
for 90 sec.  The entrance of the goal box was covered with the grey, opaque start box (a 
23 cm x 23 cm box) to prevent escape from the goal box into the maze.   
An acquisition trial began by placing the rat under the start box positioned in the 
center of the platform.  After 30 sec, the box was lifted and the rat had a maximum of 5 
min (300 sec) to find and enter the escape box.  Live observers recorded latency (time it 
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takes for the rat to enter the escape box) and total errors (nose-pokes into non-escape 
holes).  If the rat did not enter the escape box within 5 min, it was gently guided there by 
the experimenter’s hand.  After 30 sec, the rat was removed from the escape box and 
returned to its home cage.  The platform and escape box were cleaned after every trial 
with a 20% ethanol solution.  Rats were then allowed to rest in their home cage in the 
testing room for 30 min before starting their second daily trial.  After the third day, 
testing abated for 3 days, after which retention was evaluated with two additional trials (1 
day), conducted exactly like those just described.  The following day, the rats were given 
reversal training, in which the rats were given trials identical to those described above, 
except that the escape box was moved to a new location in the opposite quadrant.  
Reversal training continued for a total of three days. 
 
Elevated Plus Maze.  The elevated plus maze was made of grey-painted wood.  The 
square center area of the maze, which could lead to any of the four arms, measured 14 cm 
by 14 cm.  Each of the four arms was 43.2 long from the center area.  The two enclosed 
arms had sidewalls and an endwall that were 20 cm in height; the open arms had 
sidewalls that were 3.75 cm high and there was no wall at the end of these arms.  The 
maze was elevated 57.2 above the floor.  Each rat was placed in the central platform of 
the maze, and allowed to freely explore for 10 min.  Time spent in the open arms, time 
spent in closed arms, number of entries into open arms, and number of entries into closed 
arms was recorded.  After each trial, the maze was cleaned with 20% ethanol solution. 
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Data Analysis.  Behavioral analyses were conducted using analysis of variance 
(ANOVA) in SPSS (SPSS 21, SPSS Inc., Chicago USA).  For the Barnes maze, the 
average of each animal’s performance scores each day was used in the repeated-measures 
analysis.  Day was used as the within-subjects factor and Genotype and Sex were used as  
between-group factors.  Data from the first acquisition day were not included in the 
analysis.  For the elevated plus maze, Genotype and Sex were used as the between-group 
factors.  Differences were considered significant at p < 0.05 for all analyses.  Multiple 
comparisons were conducted using Tukey HSD tests and Greenhouse-Geisser corrections 
were used for violations in sphericity. 
 
Results and Discussion 
 
Barnes Maze. 
Acquisition.  Analysis of errors and latency during acquisition did not produce a 
significant main effect of Genotype, Sex, or Day (ps > 0.09); there were also no 
significant interactions between Day and Sex, Day and Genotype, nor three-way 
interaction (ps > 0.08).  Overall, these results suggest that the groups did not differ in 
learning during the acquisition trials (see Fig. 1 for errors and Fig. 2 for latency).  
Although it could be argued that no learning occurred during this phase as there was no 
main effect of Day, we know this is not the case because the animals made fewer errors 
and had shorter latencies during the acquisition test days than on the shaping day, as 
shown in Figures 1 and 2, respectively. 
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Figure 1.  The effect of genotype on acquisition error performance in the Barnes maze 
during Experiment 1.  All values are expressed as daily group means ± standard error of 
the mean (SEM).  There were no significant main effects or interactions during 
acquisition; however, overall error performance on the acquisition training trials was 
qualitatively better than performance during the prior shaping trials. 
Figure 2.  The effect of genotype on acquisition latency performance in the Barnes maze 
during Experiment 1.  All values are expressed as daily group means ± SEM.  There were 
no significant main effects or interactions during acquisition; however, latency 
performance on the acquisition training trials was qualitatively better than performance 
during the prior shaping trials for each group. 
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Retention.  Analysis of errors during the probe trials following the retention interval 
revealed no significant main effect of Genotype or Sex nor an interaction (ps > 0.18), as 
shown in Figure 3.  Analysis of latencies during this phase produced a significant main 
effect of Genotype (p < 0.04), but no main effect of Sex or an interaction (ps > 0.22).  
Specific comparisons revealed that APP+PS1 rats had significantly longer latencies than 
both CTL rats (p < 0.05) but not APP rats (p < 0.09), as shown in Figure 4.  APP and 
Control rats did not differ (p > 0.97) in latency scores.  Thus, the memory deficit 
evidenced by longer latencies was larger for APP+PS1 rats than APP rats, consistent with 
our hypothesis. 
 
 
Figure 3.  The effect of genotype on overall error performance in the Barnes maze during 
Experiment 1.  The acquisition and reversal bars represent overall group means ± SEM of 
all three training days, while the retention bars represent group means ± SEM of two 
probe trials.  There were no significant main effects or interactions in error performance 
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during any of the three stages of testing; however, APP+PS1 rats had a non-significant 
tendency to make more errors than APP and CTL rats in all phases of the task. 
 
Figure 4.  The effect of genotype on overall latency performance in the Barnes maze 
during Experiment 1.  The acquisition and reversal bars represent overall group means ± 
SEM of all three training days, while the retention bars represent group means ± SEM of 
two probe trials.  There was a significant main effect of Genotype during retention, 
indicating that APP+PS1 rats had significantly longer latencies than Control rats (p < 
0.05) but not APP rats (p > 0.08).  * indicates p < 0.05. 
Reversal.  During reversal learning, analysis of errors produced no significant 
interactions or main effects of Sex or Genotype (ps > 0.09); but there was a significant 
main effect of Day (p < 0.02), suggesting that error performance differed over training 
days, with animals producing more errors on training day 2.  Although group differences 
did not reach conventional levels of significance, inspection of Figure 5 reveals that 
APP+PS1 rats tended to show poorer error performance than APP animals (p < 0.08).  
Analysis of latencies produced no significant main effects or interactions (ps > 0.10), but 
inspection of Figure 6 suggests that APP+PS1 rats tended to show poorer latency 
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performance than both APP rats (p < 0.15) and Control rats (p < 0.08) as indicated by 
their higher latency times.   
 
Figure 5.  The effect of genotype on reversal error performance in the Barnes maze 
during Experiment 1.  All values are expressed as daily group means ± SEM.  There was 
no significant main effect of Genotype, but there was a main effect of Day, suggesting 
that animals produced more errors on training day 2 than on days 1 and 3. 
 
Figure 6.  The effect of genotype on reversal latency performance in the Barnes maze 
during Experiment 1.  All values are expressed as daily group means ± SEM.  There were 
no significant main effects or interactions during reversal training, but APP+PS1 rats had 
a tendency to have longer latencies than both APP rats (p < 0.15) and Control rats (p < 
0.08). 
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 Overall, these results support the initial hypotheses that nTg Controls would 
outperform Tg rats and that APP+PS1 rats would perform worse than APP rats on this 
behavioral task.  However, statistically significant group differences were only found for 
one measure, which may be due to lack of power to detect significant group differences 
because of small sample sizes.  Another factor that may have contributed to these 
findings stems from the age ranges examined in this study, which may not have been 
optimally selected; it is possible that the AD animals used in this study were too young to 
show large memory deficits and it is likely that older rats would show larger group 
differences on this behavioral task, as older rats are likely to also have increased AD-like 
neuropathology.  Nevertheless, although not statistically significant, the trends observed 
in the data do correspond to the initial hypotheses and should be evaluated further. 
 A possible advantage of this model over previous animal models of AD is that 
this model may better mimic the timing of disease onset of human AD.  Many mouse 
models develop aggressive AD-like pathology as early as 3 months of age (PDAPP: 
Dodart, Mathis, Saura, Bales, Paul, & Ungerer, 2000; TgCRND8: Janus et al., 2000 and 
Chishti et al., 2001); and as previously stated, many of these mouse models often develop 
behavioral impairments before the onset of wide-spread plaque development (Beauquis, 
Vinuesa, Pomilio, Pavía, & Saravia, 2014; Eriksen & Janus, 2007; Games, Buttini, 
Kobayashi, Schenk, & Seubert, 2006; Sterniczuk, Antle, Laferla, & Dyck, 2010; Wright 
et al., 2013).  Consequently, this time course and disease progression do not correspond 
to human AD, in which the onset is much later in life and in which substantial plaque 
pathology is probably present for some time before cognitive symptoms first appear 
(Price & Morris, 1999).  The rat models of AD used in this experiment have been shown 
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to develop significant AD-like pathology, including neurofibrillary tangles in the APP 
rats and chromatolysis in hippocampal neurons and neuronal loss in CA3 region of 
hippocampus in the APP+PS1 rats, when examined at 18-19 months of age (Agca, 
Klakotskaia, Schachtman, Chan, Lah, & Agca, 2016).  However, it is currently unclear 
whether these neuropathologies are also present at the younger age range used in the 
current experiment.  Previous studies with these models suggest that plaque formation in 
these animals is dependent on environmental challenges (Rosen et al., 2012), so it is 
likely that there was little to no significant AD-like neuropathology at the younger age 
ranges used in the current study.  Larger memory deficits are expected with the onset of 
more severe pathology; consequently, future studies should evaluate behavior in older 
animals. 
 
 Elevated Plus Maze.  Analysis of performance produced four measures:  (1) total 
time spent in the open arms (Open Arms); (2) the ratio of time spent in the open arms 
relative to the closed arms (Time Ratio); (3) the number of arm alternations 
(Alternations); and (4) the ratio of entries into the open arms relative to the closed arms 
(Entry Ratio).   
 The analysis revealed no significant main effect of Genotype (Fig. 7 and 8) or 
interaction for any of the four measures (ps > 0.20).  There was however a significant 
main effect of Sex for Open Arms (p < 0.01), Alternations (p < 0.001), and Entry Ratio (p 
< 0.02), but not Time Ratio (p > 0.76).  Females spent significantly more time in the open 
arms than the male rats, alternated between the open and the closed arms significantly 
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more frequently than male rats, and made significantly more entries into open arms 
relative to closed arms than males, as shown in Figures 9 and 10. 
 
Figure 7.  The effect of genotype on time spent in open arms and time ratio in the 
elevated plus maze during Experiment 1.  All values are expressed group means ± SEM.  
There were no significant Genotype main effects or interactions. 
 
 
Figure 8.  The effect of genotype on arm alternations and entry ratio in the elevated plus 
maze during Experiment 1.  All values are expressed group means ± SEM.  There were 
no significant Genotype main effects or interactions. 
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Figure 9.  The effect of sex on time spent in open arms and time ratio in the elevated plus 
maze during Experiment 1.  All values are expressed group means ± SEM.  There was a 
significant main effect of Sex, indicating that female rats spent significantly more time in 
the open arms than male rats (p < 0.01).  There was no sex difference in the ratio of time 
spent in the open arms relatives to the closed arms (p > 0.76).  ** indicates p < 0.01. 
 
 
Figure 10.  The effect of sex on arm alternations and entry ratio in the elevated plus maze 
during Experiment 1.  All values are expressed group means ± SEM.  There was a 
significant main effect of Sex, such that females made significantly more arm alternations 
(p < 0.001) and significantly more entries into open arms relative to closed arms (p < 
0.05) than males.  * indicates p < 0.05 and *** indicates p < 0.001. 
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 Although no predictions were made for the elevated plus maze, these results do 
support previous behavioral studies using nTg rats.  For instance, Johnston and File 
(1991) also found that female rats showed a reduced aversion to the open arms of the 
elevated plus maze compared to male rats.  However, these authors were unable to make 
a firm conclusion concerning sex differences in anxiety levels because the results of the 
different anxiety tests they used did not lead to effects in the same direction.  
Additionally, previous studies have also found that behavioral indices of anxiety can vary 
across stages of the estrous cycle in rats (Mora, Dussaubat, & Díaz-Véliz, 1996), and that 
anxiety levels are lower in the proestrus stage than the diestrus stage (Marcondes, 
Miguel, Melo, & Spadari-Bratfisch, 2001), when serum estradiol levels are higher.  
Although estrous cycles were not monitored in this study, it is possible that estrous stage 
may have influenced the results of both of these tasks.  In any case, the lack of a 
Genotype main effect confirms that differential anxiety levels did not influence the 
observed spatial learning and memory performance in the Barnes Maze. 
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EXPERIMENT 2 
 
In an attempt to further investigate AD in females, Experiment 2 examined spatial 
learning and memory and recognition memory deficits in the two novel models of AD 
using only female rats.  Given that Experiment 1 was expected to produce a learning 
deficit in the Tg rats but no such deficit was observed, Experiment 2 examined whether 
performance will be poor in more aged rats.  The Barnes maze was used to measure 
spatial learning and memory and similar to the previous experiment, it was predicted that 
both AD rat models would show spatial learning and memory deficits compared to age-
matched nTg controls, and that double Tg rats (APP+PS1) would show the most severe 
impairments.   
In addition to spatial reference memory, a different type of memory, specifically 
recognition memory, which has also been extensively shown to be impaired in various 
mouse models of AD (Alkam et al., 2008; Dodart, Mathis, & Ungerer, 1997; Greco et al., 
2010; Hale & Good, 2005; Jardanhazi-Kurutz et al., 2010; Taglialatela, Hogan, Zhang, & 
Dineley, 2009; Yuede et al., 2009; Zhang et al., 2012), was assessed in this experiment.  
To assess recognition memory, the novel object recognition task was used (Ennaceur & 
Delacour, 1988).  This test is based on the spontaneous behavior of rodents to interact 
more with a novel object than with a familiar one.  The task consists of two phases.  In 
the training phase, rats are allowed to explore two identical objects.  In the testing phase, 
one of the two identical objects is replaced by a novel object.  Rats that explore the novel 
object for a longer time period are said to have better memory of the familiar object, 
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whereas rats that explore the novel and familiar objects for the same amount of time, are 
said to have a poorer recall for the familiar object (Antunes & Biala, 2012).   
The novel object recognition task has been used to detect memory deficits in 
many mouse models of AD, including single, double, and triple Tg models, as well as 
other models (see Grayson et al., 2015 for a review).  However, it is important to point 
out that some studies have failed to find a difference in recognition memory between Tg 
animals and wild-type controls (Ardiles et al., 2012; Cheng, Low, Logge, Garner, & Karl, 
2014; Davis, Easton, Eacott, & Gigg, 2013; Heneka et al., 2006; Huang et al., 2006; 
Middei, Daniele, Caprioli, Ghirardi, & Ammassari-Teule, 2006; Scullion, Kendall, 
Marsden, Sunter, & Pardon, 2011).  The lack of deficits could be explained by the wide 
range of protocols used (e.g., varying intertrial intervals) and the nature of the animals 
studied (e.g., strain, gender, age, etc.).  Despite inconsistent results in the literature across 
AD models, the novel object recognition task is dependent on the integrity of the 
temporal region in rodents (Ennaceur, Neave, & Aggleton, 1996; Mumby, Pinel, & 
Dastur, 1993) and requires prefrontal cortical input (Ennaceur, Neave, & Aggleton, 
1997), which corresponds to the brain regions affected in human AD (Delacourte, David, 
Sergeant, Buee, & Wattez, 1999; Whitwell, Przybelski, Weigand, & Knopman, 2007).  
Thus, a good animal model of AD should ideally show deficits in the novel object 
recognition task.  Therefore, it was predicted that both AD rat models would also show 
recognition memory impairments compared to age-matched nTg controls, and that double 
Tg rats would show the most severe impairments. 
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Materials and Methods 
 
 Animals.  Female APP+PS1 (n = 12), APP (n = 17), and nTg Fischer 344  (n = 
17) rats aged 12 months and 14 months were used (see Table 2).  Similar to Experiment 
1, Tg rats were bred as previously described (Agca et al., 2008) and Fischer 344 controls 
were bred from parents obtained from Harlan (Indianapolis, IN, USA).  All procedures 
were performed in accordance with the University of Missouri's ACUC guidelines and 
the ILAR Guide for the Care and Use of Laboratory Animals.  All unspecified details 
were the same as those in Experiment 1. 
 
 Age 
Number of 12-mo Rats Number of 14-mo Rats 
G
en
ot
yp
e APP+PS1 n = 5 n = 7 
APP n = 10 n = 7 
nTg (CTL) n = 10 n = 7 
 
Table 2.  Rats used in Experiment 2.  A total of 46 rats were used. 
 
Behavioral Assessment.  Each rat was handled at least four times prior to any 
behavioral treatment to reduce anxiety due to handling during testing.  Each day on 
which behavioral testing occurred, rats were transported to the testing room from the 
colony room in their home cages and acclimated in the testing room for a minimum of 30 
min prior to the first trial.  All animals underwent the novel object recognition task first, 
followed by the Barnes maze. 
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Novel Object Recognition Task.  Two identical copies of two pairs of objects were used.  
The heights of the objects averaged 11.5 ± 1.5 cm (mean ± SEM), the diameters averaged 
7.5 ± 1 cm, and all objects weighed in excess of 400 g to prevent displacement.  One 
object was made of hexagonal shapes consisting of gray plastic and the other was a small 
clear round vase filled with marbles, as pictured in Figure 11.  The objects were placed in 
a 50.5 x 39.1 x 32.1 (l x w x h) cm white acrylic rectangle-shaped chamber 2.5 cm from 
the two short-side walls.  The objects were washed with 20% ethanol solution after each 
exposure to a rat.  
 
Figure 11.  Objects used in the novel object recognition task.  Two identical pairs of 
objects were used in this task.  The object pictured on the left was a small clear round-
shaped vase filled with marbles and the object pictured on the right was made of gray 
plastic and consisted of three layered hexagonal shapes. 
 
 The novel object recognition task procedure was as follows.  On Day 1, the rats 
were placed in the chamber (without objects) for a 20-min acclimation session.  Day 2 
involved two sessions:  A training session and a test session.  During the training session, 
the rats were placed in the apparatus with two identical objects for 3 min.  The second 
session, the test session, occurred 15 min after the training session.  The rats spent this 15 
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min retention period in the home cage.  The rats were then placed in the chamber for 3 
additional min with one object that was used in the training session and a novel object.  
The amount of time spent interacting with each object, as well as, time spent in each half 
of the chamber were recorded.  Interaction with an object was defined as the rat’s head 
being oriented towards the object and the rat’s nose being within 3 cm of the object.  
Trials were video recorded and scored by observers that were blind to the treatment status 
of the rats.  
 
Barnes Maze.  A similar Barnes maze procedure was used as in Experiment 1, with a few 
modifications to shorten the duration of the assessment.  First, the animals were only 
given a maximum of 3 min (180 sec) to find and enter the escape box, rather than 5 min 
(300 sec).  Additionally, all animals were given three trials per day, instead of two trials 
per day, again with 30 min intertrial intervals.  Lastly, similar to Experiment 1, there was 
an initial shaping day (again, data from these 3 trials were not included in the analysis), 
which was followed by three additional days of acquisition training.  However, in this 
experiment, the retention interval was increased from three days to 14 days to produce a 
greater retention effect.  The retention day was followed by three reversal training days, 
where the location of the target box was moved to the opposite quadrant. 
 
 Data Analysis.  Behavioral analyses were conducted using analysis of variance 
(ANOVA) in SPSS (SPSS 21, SPSS Inc., Chicago USA).  For the Barnes maze, daily 
latency and error performance was averaged each day and used in the repeated-measures 
analysis.  Day was used as the within-subjects factor and Genotype and Age were used as 
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between-group factors.  For the novel object recognition task, Genotype and Age were 
used as between-group factors.  An object discrimination index, calculated for each rat, 
was expressed as (TN − TF), where TN and TF were the time spent during trial 2 with the 
novel object and familiar object, respectively; a corresponding score was calculated for 
side discrimination (Antunes & Biala, 2012).  Additionally, an object recognition index, 
calculated for each rat, was expressed as the ratio (TN × 100)/(TF + TN); a corresponding 
score was calculated for side recognition (Antunes & Biala, 2012).  Differences were 
considered significant at p < 0.05 for all analyses.  Multiple comparisons were conducted 
using Tukey HSD tests and Greenhouse-Geisser corrections were used for violations in 
sphericity. 
 
Results and Discussion  
 
 Novel Object Recognition Task.  There were no significant Genotype differences 
in object discrimination or side discrimination during the training trial (ps > 0.05; data 
not shown), which indicated that there were no differences in object or side preferences 
between the identical pair of objects.  However, there was a significant main effect of 
Age in object and side discrimination during the training trial (ps < 0.05), suggesting that 
younger animals spent more time with the left object and on the left side of the chamber 
when given two identical items, which may have influenced the results of the subsequent 
test trial.  Analysis of object discrimination, side discrimination, object recognition index, 
and side recognition index, during the test trial yielded a main effect of Genotype (ps < 
0.05).  Post hoc comparisons indicated that the APP rats had a significantly larger 
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preference for the new object on the test trial than the Controls (ps < 0.05); in contrast, 
the Control rats had a significant preference for the old object, as shown in Figure 12.  
Paradoxically, these results suggest better memory in APP rats than in Control rats.  
APP+PS1 also tended to have a preference for the new object, but their preference was 
not significantly different from Controls (p > 0.14).  Although there was a significant 
main effect of Genotype for side discrimination (p < 0.05), post hoc comparisons did not 
reveal any significant group differences (ps > 0.05), but suggested that Controls had a 
non-significant preference for the old side compared to both of the other groups (ps < 
0.07). 
 
Figure 12.  The effect of genotype on object and side discrimination in the novel object 
recognition task during Experiment 2.  All values are expressed group means ± SEM.  
There was a significant main effect of Genotype, indicating a significantly larger 
preference for the old object in the Control rats compared to the APP rats.  Control rats 
also had a non-significant preference for the old side than both the APP and APP+PS1 
animals (ps < 0.07).  * indicates p < 0.05. 
 
For the recognition indices, an index above 50% indicates a novel object/side 
preference, an index below 50% indicates a familiar object/side preference, and an index 
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APP rats had a significantly stronger preference for the novel object than the Controls (p 
< 0.03) according to this index, and therefore, outperformed Controls on this task, as 
shown in Figure 13.  To explore whether differential exploratory behavior could be 
responsible for the differences in object discrimination, the times spent not exploring 
either object were also compared between the groups and no differences were seen (p > 
0.05; data not shown).  Lastly, there were no significant age differences between the 12-
month old and 14-month old animals (Figs. 14 and 15) or an interaction between 
Genotype and Age for any of the measures (ps > 0.18). 
 
Figure 13.  The effect of genotype on object and side recognition indices in the novel 
object recognition task during Experiment 2.  All values are expressed group means ± 
SEM.  APP rats had a significantly stronger preference for the novel object than the 
Control rats.  Although there were no significant group differences in side recognition, 
Control rats showed a non-significant preference for the familiar side.  * indicates p < 
0.05. 
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Figure 14.  The effect of age on object and side discrimination in the novel object 
recognition task during Experiment 2.  All values are expressed group means ± SEM.  
There were no significant group differences. 
 
Figure 15.  The effect of age on object and side recognition indices in the novel object 
recognition task during Experiment 2.  All values are expressed group means ± SEM.  
There were no significant group differences. 
 
There was no evidence of poor memory using the novel object recognition task 
for Tg rats.  In fact, unexpectedly, the APP and APP+PS1 rats exhibited behavior that 
would be indicative of better memory relative to Control animals.  These results are 
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previous studies have failed to find a difference in recognition memory between Tg 
animals and wild-type controls (Cheng, Low, Logge, Garner, & Karl, 2014; Davis, 
Easton, Eacott, & Gigg, 2013; Heneka et al., 2006; Huang et al., 2006; Middei, Daniele, 
Caprioli, Ghirardi, & Ammassari-Teule, 2006; Scullion, Kendall, Marsden, Sunter, & 
Pardon, 2011) as stated earlier, there is no evidence in the literature for a reversed effect 
like the one observed in this study.  Although anxiety was not measured in this study, 
Experiment 1 found that females showed significantly less anxiety in the elevated plus 
maze than males, which might suggest a lack of anxiety toward novel objects in all of the 
animals used in this study.  For example, Frick and Gresack (2003) found that male 
C57BL/6 mice showed a strong preference for the novel object in a similar paradigm, 
whereas females exhibited no preference.  Such sex differences could be explained by 
sexual dimorphisms in a number of relevant brain regions like the neocortex, 
hippocampus, and septum (Baker & Kim, 2002; Clark, Zola, & Squire, 2000; Ennaceur & 
Aggleton, 1997).  However, this explanation would suggest no group differences on any 
of the novel object recognition task measures, so it does not explain the significant 
differences observed in this study.  It is also possible that the preference for the novel 
object in the Tg animals was due to decreased neophobia; however, it is important to note 
that this is inconsistent with previous studies that have found more neophobia to stimuli 
in AD rats than wild-type littermates (España et al., 2010; Hsiao et al., 1995; Moechars et 
al., 1999).  
Lastly, it is also likely that these results are contingent upon the specific protocol 
used in this study.  For example, it is possible that the 20-min acclimation session before 
the training trial was too long, which may have caused habituation with the chamber and 
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thus less exploration of either of the objects or sides on the subsequent trials the 
following day.  Thus, subsequent studies may wish to use a shorter acclimation period.   
 
Barnes Maze.   
Acquisition.  Analysis of errors and latency during acquisition produced a main effect of 
both Genotype (ps < 0.05) and Day (ps < 0.01), but there was no significant effect of Age 
for either measure (ps > 0.23).  Additionally, there was a significant three-way interaction 
for errors (p < 0.05), but not latency (p > 0.24) and no other significant interactions (ps > 
0.28).  Both error and latency performance significantly improved across days as shown 
in Figures 16 and 17, and Control animals made significantly fewer errors than APP (p < 
0.002) and APP+PS1 animals (p < 0.02), as shown in Figure 18.   
 
Figure 16.  The effect of genotype on acquisition error performance in the Barnes maze 
during Experiment 2.  All values are expressed as daily group means ± SEM.  Error 
performance significantly improved over days (p < 0.01). 
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Figure 17.  The effect of genotype on acquisition latency performance in the Barnes 
maze during Experiment 2.  All values are expressed as daily group means ± SEM.  
Latency performance improved over days (p < 0.001). 
 
Figure 18.  The effect of genotype on overall error performance in the Barnes maze 
during Experiment 2.  The acquisition and reversal bars represent overall group means ± 
SEM of all three training days, while the retention bars represent group means ± SEM of 
three probe trials.  There was a significant main effect of Genotype for all phases of the 
testing, such that nTg rats made significantly fewer errors than Tg rats.  However, 
Control animals did not differ from APP animals during retention.  * indicates p < 0.05 
and ** indicates p < 0.01. 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
 Day 1   Day 2   Day 3 
Ti
m
e 
(s
ec
) 
CTL APP APP+PS1 
** 
** 
* ** 
* 
* 
0 
5 
10 
15 
20 
25 
 Acquisition     Retention        Reversal       
N
um
be
r o
f E
rr
or
s 
CTL APP APP+PS1 
   
	
38 
Surprisingly, however, Controls also had significantly longer latencies than 
APP+PS1 animals (p < 0.04), as shown in Figure 19.  The trend was different than what 
was expected, such that Control rats showed the longest latencies and the APP+PS1 rats 
showed the shortest latencies during acquisition.  This finding may have stemmed from 
the modified Barnes maze procedure used in this experiment.  The protocol in this 
experiment used shorter trials with more trials per day than the previous experiment.  The 
shorter trial length may have substantially reduced the average entry latencies of the Tg 
animals in a way that benefited their overall latency performance.  Further, the additional 
exposure to the maze via the extra trial per day may have had a detrimental effect on the 
performance of the nTg Control animals.  It is possible that the Control animals were no 
longer sufficiently aversively stimulated by the Barnes Maze environment and thus 
unmotivated to complete the maze.  This explanation seems plausible given that the 
Controls only had longer latencies but did not produce many errors.  Subsequent studies 
may consider adding additional aversive stimuli to the testing environment such as white 
noise or a fan to improve motivation in the Control rats. 
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Figure 19.  The effect of genotype on overall latency performance in the Barnes maze 
during Experiment 2.  The acquisition and reversal bars represent overall group means ± 
SEM of all three training days, while the retention bars represent group means ± SEM of 
three probe trials.  There was a significant main effect of Genotype during acquisition, 
indicating that Control rats had significantly longer latencies than APP+PS1 rats (p < 
0.05) but not APP rats (p > 0.05).  There were no significant group differences during 
retention or reversal training.  * indicates p < 0.05. 
Retention.  Error performance during the retention test produced significant main effects 
of Genotype (p < 0.004; Fig. 18) and Age (p < 0.02), as well as an interaction between 
Genotype and Age (p < 0.004).  There was also a significant main effect of Age (p < 
0.05) but not Genotype (p > 0.55; Fig. 19) for latency.  Post hoc comparisons indicated 
that APP+PS1 rats made statistically more errors than both APP (p < 0.03) and Control 
animals (p < 0.001) and that 14-month old rats made significantly more errors (p < 0.02) 
and had significantly longer latencies than 12-month old rats (p < 0.05), as shown in 
Figures 18 and 20 respectively.   
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Figure 20.  The effect of age on retention performance in the Barnes maze during 
Experiment 2.  All bars are expressed as group means ± SEM.  There was a significant 
main effect of Age for both errors and latencies, suggesting that 14-month old rats 
performed significantly worse than 12-month old rats.  * indicates p < 0.05. 
Reversal.  Analysis of error performance during reversal training found a significant 
interaction between Day and Genotype (p < 0.02) and a main effect of Day (p < 0.001), 
indicating that errors for all groups declined with reversal training as shown in Figure 21.  
There was also a significant main effect of Genotype (ps < 0.04) and Age (ps < 0.05) for 
both measures, suggesting that Control animals made significantly fewer errors than both 
APP (p < 0.001) and APP+PS1 animals (p < 0.003) as shown in Figure 18, and that 14-
month old animals made significantly more errors and had significantly longer latencies 
than 12-month old rats (ps < 0.05) as shown in Figure 22; the Age effect, however, did 
not vary as a function of Genotype for either measure (ps > 0.46).  Post hoc comparisons 
did not find any significant Genotype differences for latencies, but suggested that 
APP+PS1 rats had a non-significant tendency to have shorter latencies than both the 
Control (p < 0.09) and the APP rats (p < 0.12), as shown in Figure 23.  Again, this effect 
in the latency data may stem from differential motivation to complete the maze as 
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suggested earlier.  Although anxiety levels were not found in Experiment 1, other studies 
have found that AD animals tend to have higher levels of anxiety (Beauquis et al., 2014; 
Blázquez et al., 2014; Pietropaolo, Feldon, & Yee, 2014; Sterniczuk et al., 2010) and 
thus, it is possible that AD animals continue to be motivated to escape the aversive nature 
of the Barnes maze even after so many training trials, whereas the Control animals may 
learn that the maze environment is no longer fear-inducing after being exposed to it on so 
many previous trials. 
 
Figure 21.  The effect of genotype on reversal error performance in the Barnes maze 
during Experiment 2.  All bars are expressed as group means ± SEM.  There was a 
significant main effect of Day, indicating that the number of errors made declined with 
reversal training (p < 0.001). 
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Figure 22.  The effect of age on reversal performance in the Barnes maze during 
Experiment 2.  All bars are expressed as group means ± SEM.  There was a significant 
main effect of Age, indicating that older animals made significantly more errors and had 
significantly longer latencies than younger animals (ps < 0.05).  * indicates p < 0.05. 
 
Figure 23.  The effect of genotype on reversal latency performance in the Barnes maze 
during Experiment 2.  All bars are expressed as group means ± SEM.  Although there 
were no significant group differences, APP+PS1 rats had a non-significant tendency to 
have shorter latencies than both the Control (p < 0.09) and the APP rats (p < 0.12). 
Overall, in terms of error performance, APP and APP+PS1 rats showed poor 
memory for the location of the escape box during acquisition, retention, and reversal in 
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the Barnes maze.  This result is consistent with many spatial learning findings using 
rodent models of AD (Blázquez, Cañete, Tobeña, Giménez-Llort, & Fernández-Teruel, 
2014; Cañete, Blázquez, Tobeña, Giménez-Llort, & Fernández-Teruel, 2015; 
Stepanichev et al., 2004; Stewart, Cacucci, & Lever, 2011; Wright et al., 2013), including 
performance in the Barnes maze (Attar et al., 2013; O'Leary & Brown, 2009; Reiserer, 
Harrison, Syverud, & McDonald, 2007; Stover, Campbell, Van Winssen, & Brown, 
2015; Walker et al., 2011; Walker et al., 2015).   
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EXPERIMENT 3 
 
After examining the behavioral characteristics of these two novel rat models for 
AD and having established that they are good models of the disorder using the previous 
experiments, the purpose of this final study was to use these models to further elucidate 
the link between gender and AD.  As such, Experiment 3 examined the effects of 
decreased endogenous estrogen levels in females on memory performance. 
Although the role of sex steroids in brain development and reproductive behavior 
has long been recognized, the importance of these steroids on older adult brain function 
has only recently been examined (Ball & Birge, 2002).  In addition to its role as a 
reproductive hormone, estrogen has been shown to a play neuroprotective and 
neuromodulatory role in the brain.  For example, estrogen is involved in the control of 
neuronal functions such as neuronal proliferation, neuronal survival, and neuronal 
plasticity (Bhavnani, 2003; Brann, Dhandapani, Wakade, & Mahesh, 2007).  
Furthermore, estrogen receptors are expressed in brain regions vulnerable to AD, such as 
the hippocampus and the neocortex (Galea et al., 2013; Lee, Jiang, Han, Shin, & Choi, 
2014; Shughrue, Scrimo, Lane, Askew, & Merchenthaler, 1997).  Evidence also shows 
that estrogen can play an important neuroprotective role in AD as it may reduce Aβ 
levels, or prevent them from rising, in the presence of pathological triggers (Anastasio, 
2013).  Hence, it has been suggested that the reduction of estrogen levels during aging, 
especially during the postmenopausal period in women, induces progressive 
neurodegeneration in the brain and results in cognitive impairment (Brann et al., 2007; 
Fukuzaki et al., 2008; Paganini-Hill & Henderson, 1994).   
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Experimental animals provide a model for investigating age-related effects of 
estrogen on brain function.  Previous research has found that hippocampal estradiol 
treatment in middle-aged and aged female rodents increases levels of synaptophysin, 
which has been associated with improved spatial reference memory performance (Frick, 
Fernandez, & Bulinski, 2002).  Estradiol treatment can also block the induction of long-
term depression (Foster, Sharrow, Kumar, & Masse, 2003), which may be the mechanism 
through which estradiol improves memory in aging females.  In addition, the literature on 
estrogen deficiency has found that ovariectomy in middle-aged rats results in a decline in 
both spatial and non-spatial memory performance (Heikkinen et al., 2004; Markowska & 
Savonenko, 2002; Sato et al., 2003; Wallace, Luine, Arellanos, & Frankfurt, 2006) and 
active avoidance behavior (Singh, Meyer, Millard, & Simpkins, 1994).  Physiologically, 
estrogen deficiency through ovariectomy has been found to result in the production of 
neurofibrillary tangles and amyloid deposition in rats (Anukulthanakorn, Malaivijitnond, 
Kitahashi, Jaroenporn, & Parhar, 2013).  Furthermore, there is evidence to suggest that 
such cognitive deterioration can be prevented by estrogen replacement.  Estradiol 
administration to ovariectomized rats is associated with enhanced performance on a 
number of tasks (Cost, Williams-Lee, Fustok, & Dohanich, 2012; Gibbs et al., 2004; 
Iivonen et al., 2006; Luine, Jacome, & Maclusky, 2003; Markowska & Savonenko, 2002; 
Rhodes & Frye, 2004; Singh et al., 1994), further highlighting the potential benefits of 
estrogen.   
These multiple effects of estrogen on brain function seem to suggest an effective 
strategy to prevent and treat AD.  To further characterize our novel rat models as valuable 
models of AD, this study examined the effects of estrogen deficiency in these models on 
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spatial learning and memory and recognition memory.  Both AD models and nTg 
controls underwent either an ovariectomy or sham surgery, after which, spatial learning 
and memory and recognition memory were assessed.  As before, the Barnes maze and the 
novel object recognition task were used to assess behavior.  Assessment occurred 
approximately 6 months after the surgeries based on previous findings that have shown 
that deterioration in memory performance is not evident until at least 3 to 4 months after 
ovariectomy (Singh et al., 1994).  It was predicted that Tg (APP and APP+PS1) animals 
would show greater memory deficits than nTg controls, and that the APP+PS1 rats would 
have the most severe memory impairments on both tasks.  Additionally, it was predicted 
that ovariectomized animals would show more deficits than their sham controls, and that 
ovariectomy would have the largest detrimental effect on the APP rats.  The reasoning 
underlying this hypothesis was that the APP+PS1 animals were expected to have the 
worst overall behavioral performance, possibly near floor level; thus, there may be no 
room for their performance to decline any further.  Estrogen deficiency was predicted to 
not have much of an effect on the control animals as they do not have any AD pathology.  
Therefore, estrogen deficiency was expected to have the largest effect on the single Tg 
(APP) animals. 
 
Materials and Methods 
 
 Animals.  Similar to the previous experiments, female APP+PS1 (n = 25), APP (n 
= 21), and nTg Fischer 344 (n = 28) rats were used.  Tg rats were bred as previously 
described (Agca et al., 2008) and Fischer 344 controls were obtained from Harlan 
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(Indianapolis, IN, USA) at 3 weeks of age.  To manipulate estrogen deficiency at six 
weeks of age, half of the animals in each group underwent an ovariectomy surgery while 
the other half underwent a sham surgery (see Table 3).  All procedures were performed in 
accordance with the University of Missouri's ACUC guidelines and the ILAR Guide for 
the Care and Use of Laboratory Animals.  All unspecified details were the same as those 
in Experiment 2. 
 
 Estrogen 
Number of Sham Rats Number of OvX Rats 
G
en
ot
yp
e APP+PS1 n = 12 n = 13 
APP n = 12 n = 9 
nTg (CTL) n = 14 n = 14 
 
Table 3.  Rats used in Experiment 3.  A total of 74 rats were used. 
 
Behavioral Assessment.  Behavioral testing occurred starting at 8 months of age, 
or 6.5 months after surgeries.  Each rat was handled at least four times prior to any 
behavioral treatment to reduce anxiety due to handling during testing.  Each day on 
which behavioral testing occurred, rats were transported to the testing room from the 
colony room in their home cages and acclimated in the testing room for a minimum of 30 
min prior to the first trial.  The behavioral treatment order (Barnes maze and novel object 
recognition Task) was counterbalanced for all rats. 
 
Novel Object Recognition Task.  A similar novel object recognition task procedure was 
used as in Experiment 2, with one minor modification.  Instead of a 20-min acclimation 
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session on Day 1, rats received a 10-min acclimation session as to ensure high levels of 
activity during subsequent sessions. 
 
Barnes Maze.  A similar Barnes maze procedure was used as in Experiment 1, with a few 
modifications.  First, the animals were again given a maximum of 5 min (300 sec) to find 
and enter the escape box.  Additionally, all animals were given two trials per day, again 
with 30 min intertrial intervals.  Lastly, there was an initial training day with only one 
trial (data from this trial were not included in the analysis), which was followed by four 
additional days of acquisition training.  Additionally, the retention interval in this 
experiment was 14 days.  The retention day was followed by four reversal training days 
where the location of the target box was moved to the opposite quadrant. 
 
Data Analysis.  Behavioral analyses were conducted using analysis of variance 
(ANOVA) in SPSS (SPSS 21, SPSS Inc., Chicago USA).  For the Barnes maze, the 
average of each animal’s performance scores each day was used in the repeated-measures 
analysis.  Day was used as the within-subjects factor and Genotype and Estrogen were 
used as between-group factors.  For the novel object recognition task, Genotype and 
Estrogen were used as between-group factors.  Differences were considered significant at 
p < 0.05 for all analyses.  Multiple comparisons were conducted using Tukey HSD tests 
and Greenhouse-Geisser corrections were used for violations in sphericity. 
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Results and Discussion 
 
Novel Object Recognition Task.  There were no significant Genotype differences 
in object discrimination or side discrimination during the training trial (ps > 0.90; data 
not shown); however, there was a significant main effect of Estrogen in side 
discrimination during the training trial, suggesting that Sham animals had a preference 
for the left side of the chamber and OvX animals had a preference for the right side 
during the initial training trial, which may have affected the subsequent test trial results.  
During the test trial, there were no significant main effects of Genotype (ps > 0.53; Fig. 
24 and 25) or Estrogen (p > 0.68; Fig. 26 and 27), or any interactions (ps > 0.17) for any 
of the four variables. 
 
Figure 24.  The effect of genotype on object and side discrimination in the novel object 
recognition task during Experiment 3.  All values are expressed group means ± SEM.  
There were no significant group differences. 
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Figure 25.  The effect of genotype on object and side recognition indices in the novel 
object recognition task during Experiment 3.  All values are expressed group means ± 
SEM.  There were no significant group differences. 
 
 
 
Figure 26.  The effect of estrogen on object and side discrimination in the novel object 
recognition task during Experiment 3.  All values are expressed group means ± SEM.  
There were no significant group differences. 
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Figure 27.  The effect of estrogen on object and side recognition indices in the novel 
object recognition task during Experiment 3.  All values are expressed group means ± 
SEM.  There were no significant group differences. 
 
Although these results do not support the initial hypothesis, they do align with 
previous findings in the literature that have failed to find differences in recognition 
memory between Tg animals and wild-type controls (Ardiles et al., 2012; Cheng, Low, 
Logge, Garner, & Karl, 2014; Davis, Easton, Eacott, & Gigg, 2013; Heneka et al., 2006; 
Huang et al., 2006; Middei, Daniele, Caprioli, Ghirardi, & Ammassari-Teule, 2006; 
Scullion, Kendall, Marsden, Sunter, & Pardon, 2011).  This outcome suggests that the 
novel object recognition task may not be a sensitive measure to gauge the behavioral 
impairments observed in these rat models of AD. 
 
Barnes Maze.   
Acquisition.  Analysis of errors and latencies during acquisition produced a main effect of 
Day (ps < 0.001), indicating that performance improved over training trials, as shown in 
Figures 28 and 29.  There was also a significant main effect for Genotype in error 
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performance (p < 0.02) but not in latency performance (p > 0.61), revealing that Controls 
made significantly fewer errors than APP rats (p < 0.04), but not APP+PS1 animals (p > 
0.07), as seen in the leftmost acquisition bars in Figure 30.  There was also a significant 
main effect of Estrogen in latency performance (p < 0.04) but not in error performance (p 
> 0.53), suggesting that Sham animals had significantly lower latencies than OvX 
animals during acquisition, as shown in the acquisition latency bars (fourth set of bars 
from the left) in Figure 31.  Overall, Controls made statistically fewer errors and had 
numerically shorter latencies than Tg rats during the acquisition phase, which is 
consistent with the initial hypothesis that Control rats would outperform Tg rats and 
supports previous Tg research.  Additionally, the finding that OvX animals would 
perform worse than Shams was also expected and consistent with previous spatial 
memory research (Heikkinen et al., 2004; Markowska & Savonenko, 2002; Sato et al., 
2003; Wallace, Luine, Arellanos, & Frankfurt, 2006). 
 
Figure 28.  The interaction of genotype by estrogen on acquisition error performance 
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over training days in the Barnes maze during Experiment 3.  All values are expressed as 
daily group means ± SEM.  Error performance significantly improved over days (p < 
0.001). 
 
Figure 29.  The interaction of genotype by estrogen on acquisition latency performance 
over training days in the Barnes maze during Experiment 3.  All values are expressed as 
daily group means ± SEM.  Latency performance significantly improved over days (p < 
0.001). 
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Experiment 3.  The acquisition and reversal bars represent overall group means ± SEM of 
all four training days, while the retention bars represent group means ± SEM of two 
probe trials.  Control rats made significantly fewer errors than APP (p < 0.04) but not 
APP+PS1 rats (p < 0.07) during acquisition.  During retention, APP rats made 
significantly more errors (p < 0.04) and had longer latencies (p = 0.05) than Controls, but 
not APP+PS1 rats (ps > 0.14).  During reversal, APP+PS1 animals made significantly 
more errors than Control animals (p < 0.002) but not APP animals (p > 0.14) and had 
significantly longer latencies than APP animals (p < 0.03) but not Controls (p > 0.31).  * 
indicates p < 0.05 and ** indicates p < 0.01. 
 
Retention.  Both error and latency performance during the retention test produced 
significant main effects of Genotype (ps < 0.05; Fig. 30), but not Estrogen (ps > 0.68; 
Fig. 31), and no significant interactions (ps > 0.23).  Post hoc comparisons that collapsed 
over estrogen indicated that APP rats made significantly more errors (p < 0.04) and had 
statistically longer latencies (p = 0.05) than Control animals during the retention test, as 
shown in Figure 30.  APP+PS1 rats did not differ from the other two groups on these two 
measures (ps > 0.14). 
 
Figure 31.  The effect of estrogen on overall latency performance in the Barnes maze 
during Experiment 3.  The acquisition and reversal bars represent overall group means ± 
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SEM of all four training days, while the retention bars represent group means ± SEM of 
two probe trials.  There was a significant main effect of Estrogen in latency during both 
acquisition and reversal, showing that OvX animals had significantly longer latencies 
than Sham animals (p < 0.05).  There were no significant estrogen differences for latency 
performance during retention or for error performance in any phase of training.  * 
indicates p < 0.05. 
 
Reversal.  Analysis of error performance during reversal training found 
significant main effects of Day (p < 0.005; Fig. 32) and Genotype (p < 0.002; Fig. 30) 
and two-way interactions between Day and Estrogen and Genotype and Estrogen (ps < 
0.05).  Analysis of latency performance during reversal training found significant main 
effects of Day (p < 0.002; Fig. 33) and Estrogen (p < 0.05; Fig. 31), and a three-way 
interaction (p < 0.001).  It was found that OvX animals had significantly longer latencies 
than Sham animals (p < 0.05), as seen in the rightmost bars of Figure 31.  Additionally, 
post hoc comparisons revealed that APP+PS1 animals made significantly more errors 
than Control animals (p < 0.002) but not APP animals (p > 0.14), and had significantly 
longer latencies than APP animals (p < 0.03) but not Controls (p > 0.31), as shown in 
Figure 30.  
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Figure 32.  The interaction of genotype by estrogen on reversal error performance over 
training days in the Barnes maze during Experiment 3.  All values are expressed as daily 
group means ± SEM.  Error performance significantly improved over days (p < 0.005). 
 
Figure 33.  The interaction of genotype by estrogen on reversal latency performance over 
training days in the Barnes maze during Experiment 3.  All values are expressed as daily 
group means ± SEM.  Latency performance significantly improved over days (p < 0.002). 
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 In addition to replicating the genotype differences from the previous experiments, 
Experiment 3 found that estrogen deficiency exacerbated AD symptoms in the Tg rat 
models, as evidenced by longer latencies in the Barnes maze.  This finding is consistent 
with previous studies of neuronal cell cultures and rodent models that propose a 
protective effect of estrogen in AD (e.g. Anastasio, 2013; Behl, Widmann, & Holsboer, 
1995; Xu et al., 1998).  More importantly, however, it was found that estrogen deficiency 
had a larger detrimental effect on the APP rats than the APP+PS1 rats, as predicted; the 
effect is most clearly illustrated in Figures 32 and 33.  As previously discussed, this could 
be due to the fact that both APP+PS1 groups performed closer to floor level due to their 
more severe AD-like impairments.  In many cases, the APP sham animals performed 
comparably to the two Control groups, and therefore, the detrimental effect of estrogen 
deficiency could be seen most clearly in this genotype group.  This finding implies that 
the APP Tg model may be useful in testing the detrimental effects of certain treatments 
on AD onset and progression.  On the other hand, the APP+PS1 model may be better 
suited towards evaluating the effectiveness of therapies that might benefit AD symptoms 
and progression. 
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GENERAL DISCUSSION 
 
As human life expectancy increases, the prevalence of AD is expected to rise 
(Hebert et al, 2003); this makes AD a growing public-health concern, as there are no 
known cures to treat the disease (Reitz, 2012).  One reason for the lack of progress 
towards developing a cure is that there are currently no animal models that completely 
capture the full-spectrum of human AD pathology, which makes it difficult to evaluate 
the efficacy of new therapies.  This paper addressed the development of two new Tg rat 
models for the disease and evaluated whether they display the behavioral deficits of AD.   
The results of the present studies and other physiological studies with these Tg 
rats suggest that these models may be more accurate models of the disease than the Tg 
models that are currently widely-used in the literature.  The combined results of 
Experiment 1 and 2 found that these models showed significant memory deficits in 
performance in the Barnes maze.  Error performance tended to be a more consistent 
measure of spatial learning and memory rather than latency, possibly due to genotype 
motivational differences.  It was also found that the 12-14 month age range used in 
Experiment 2 was more sensitive to genotype differences than the 8-12 month age range 
used in Experiment 1.  More specifically, Experiment 1 found significant genotype 
differences only during the retention phase of the Barnes maze in the 8-12 month old rats, 
whereas the Experiment 2 found significant genotype differences in all three phases of 
the Barnes maze for 12-14 month old rats.  This finding highlights the importance of 
measuring memory ability across the entire lifespan of the animal and correlating 
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memory loss with molecular markers appearing at different stages of disease (Ashe, 
2001).   
As previously mentioned, histological examinations of these models have found 
that the APP rats display significant neurofibrillary tangles and that the APP+PS1 rats 
show chromatolysis and neuronal loss in the hippocampus (Agca et al., 2016) at 18-19 
months of age.  These physiological markers are consistent with human AD pathology 
(Ball, 1977; Gómez‐Isla et al., 1997; West, 1993; West, Coleman, Flood, & Troncoso, 
1994).  Another advantage of the present APP rat model is that it is able to mimic the 
gradual timing of disease onset more accurately than current mouse models, most of 
which develop aggressive early-onset AD-like pathology.  A previous study using the 
present APP rats suggested that this model does not exhibit Aβ plaque formation unless 
there is an additional environmental challenge (Rosen et al., 2012), similar to how human 
AD patients may not display clinical symptoms until there is an additional physiological 
disturbance, such as a stroke.  Additionally, the only AD mouse models that develop 
neurofibrillary tangles to date are those that express mutant forms of tau, even though no 
cases of human AD are linked to mutations in tau (as reviewed by Ashe, 2001).  Thus, the 
observance of neurofibrillary tangles in an APP-alone Tg rat is noteworthy and may be 
the largest indication that the present APP rat model may have distinct advantages over 
models currently used in the field. 
The present models, nevertheless, are not without fault.  As discussed earlier, Aβ 
burden is often present in human patients with AD for some time before the manifestation 
of clinical impairments (Bateman et al., 2012; Price & Morris, 1999).  Unfortunately, the 
present APP model does not naturally develop Aβ plaques, which does not correspond 
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with the time-dependent progression of pathology of human AD.  However, it is 
important to highlight that the relationship between Aβ burden and cognitive symptoms 
is by no means clear (Foley et al., 2015), and therapeutic approaches to reduce Aβ 
production or Aβ aggregation have thus far been disappointing (Doody et al., 2013; 
Holmes et al., 2008; Salloway et al., 2014).  Hence, this model may provide new insights 
into this puzzling issue.  There is another disadvantage to the present APP rat model.  As 
previously mentioned, cognitive impairment seems to be strongly related to excessive 
neuronal loss (Terry, 2006), an AD feature many current single transgenic mouse models 
(i.e., PDAPP, Tg2576) lack despite having extensive amyloid deposition (Irizary, 
McNamara, Fedorchak, Hsiao, & Hyman, 1997; Irizarry et al., 1997).  This disadvantage, 
unfortunately, is also true for the current APP model, as previous examinations of their 
brain tissue have not yet shown evidence of significant neuronal loss (Agca et al., 2016).  
Evidence of substantial neuronal loss has only been observed in the APP+PS1 rats (Agca 
et al., 2016).   
Despite these drawbacks, the present Tg rat models do provide a slightly different 
framework than existing models and have the potential to add new perspectives to the 
existing AD literature.  As such, these models were used to investigate the link between 
sex and AD.  Due to the abundance of studies that suggest a neuroprotective effect of 
estrogen, the influence of estrogen deficiency via ovariectomy on AD cognitive 
symptoms was evaluated.  It was found that estrogen deficiency exacerbated AD 
symptoms in the Tg rat models, as evidenced by longer latencies in the Barnes maze.  
More importantly, however, estrogen deficiency had a larger detrimental effect on the 
APP rats, as predicted.  This finding implicates differential utility of each of the Tg 
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models.  The single Tg APP model may be useful in testing the detrimental effects of 
certain treatments on AD onset and progression.  On the other hand, the double Tg 
APP+PS1 model may be better suited towards evaluating the effectiveness of therapies 
that might benefit AD symptoms and progression. 
Although there is mounting evidence from cellular and animal models, as well as 
human observational studies (e.g., Rocca, Grossardt, & Shuster, 2011), that speaks to the 
neuroprotective effects of estrogen in AD, including the present study, clinical human 
trial data remain controversial.  At first, studies showed a promising effect of the use of 
hormone replacement therapy (HRT; Fillit, 2002; Paganini-Hill & Henderson, 1996; 
Tang et al, 1996), which involves the administration of synthetic estrogen and 
progesterone to replace a woman’s depleting hormone level, in postmenopausal women 
to reduce the risk of AD or delay the onset of the disease.  However, the beneficial effects 
of HRT have been challenged by the results of the Women’s Health Initiative Memory 
Study (WHIMS), a study that was ended early due to reported detrimental effects of long-
term HRT use (Manson et al., 2013; Shumaker et al., 2003).  WHIMS participants were 
recruited from among participants in the Women’s Health Initiative trials, who were ages 
65 to 79 years and without dementia at baseline.  The results found that for women with a 
uterus that received combined estrogen-progesterone therapy, there was a two-fold 
increase in dementia after 4.2 years of HRT, as well as, increased risks for breast cancer, 
pulmonary embolism, and stroke (Taylor & Manson, 2011).  For women without a uterus 
that received estrogen-alone therapy, incidence of dementia did not differ significantly 
between the two treatment groups.  A more recent randomized, double-blind, placebo-
controlled trial using raloxifene, an oral selective estrogen receptor modulator (SERM), 
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found no cognitive benefit in postmenopausal women with mild to moderate AD after 12 
months of treatment (Henderson et al., 2015).  These findings further the debate 
regarding the risk-benefit ratio of hormone therapy. 
There have been several important criticisms of the of the WHIMS study.  The 
first is directed towards the synthetic nature of the hormones administered, as well as, the 
route of administration and dose.  Critics have argued that transdermal administration 
(e.g., Asthana et al., 1999) and the use of natural hormones are more effective than the 
conjugate equine estrogen (CEE) and medroxyprogesterone acetate (MPA) used in the 
study (e.g. Kaari et al., 2006).  However, the largest criticism focuses on the age of the 
participants of the WHIMS study.  Estrogen therapy may not have universal utility in 
treating or preventing dementia and a growing number of studies support the existence of 
the “critical window of opportunity” (Gibbs, 2000b; Resnick & Maki, 2000; Resnick & 
Henderson, 2002; see Maki, 2013 and Rocca et al., 2011 for an overview), which states 
that there is a limited period after menopause during which hormone therapy is effective.  
The primary criticism of the WHIMS study is that the intervention may have been 
initiated after the critical window of opportunity and at a point at which the brain was no 
longer responsive to sex hormones.  According to this argument, hormone therapy exerts 
its beneficial effects only if begun near the time of menopause.  Since most participants 
of the WHIMS study were many years beyond menopause, this hypothesis could explain 
the absence of a beneficial neural effect of hormone therapy.  Further, the WHIMS 
findings may be valid for women with similar characteristics to those of the trial 
participants but may not generalize to much younger women who initiate hormone 
therapy much closer to the time of menopause (Henderson, 2006). 
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The critical window notion of an age-related loss in brain responsiveness to 
estrogen is supported by several animal studies.  One study found that estradiol and 
estradiol plus progesterone replacement was associated with improved spatial memory in 
a delayed match task in OvX animals when administered within 3 months post-OvX, but 
not when treatment was delayed 10 months post-OvX (Gibbs, 2000a).  Additionally, 
estradiol given immediately after OvX improved spatial memory performance in the 
radial arm maze in rats, but had no significant effect when given 5 months after OvX 
(Daniel, Hulst, & Berbling, 2006).  These data suggest that the brain can show reduced 
hormone responsiveness after an extended period of hormone depletion, however, further 
work is required to elucidate the key factors and mechanisms underlying these effects 
(Pike et al., 2009). 
More recent human studies have found similar beneficial effects of initiating 
estrogen-based hormone therapy close to the onset of menopause.  One longitudinal study 
by Bove and colleagues (2014) reported that earlier surgical menopause was associated 
with faster decline in global cognition and increased AD neuropathology.  More 
importantly, the use of HRT for at least 10 years in those with surgical menopause, when 
initiated within a 5-year postmenopausal window, was associated with decreased decline 
in cognition.  Another study reported by Wroolie, Kenna, Williams, and Rasgon (2015) 
used women aged between 49-69 who had initiated HRT close to menopause onset and 
had been taking HRT for at least one year.  All women underwent cognitive assessment 
before randomization to continue or discontinue HRT.  They found that women who 
continued HRT performed better on cognitive tests at the 2-year follow-up assessment 
than those that discontinued therapy.  Additionally, women that used 17β-E, whether 
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randomized to continue or discontinue treatment, showed better performance than women 
that used CEE.  These results suggest that continuation of HRT seems to protect 
cognition in women with a heighten risk for AD when initiated close to menopause onset, 
which lends further support to the window of opportunity hypothesis. 
Current ongoing prospective randomized placebo-controlled trials will formally 
test the critical window of opportunity hypothesis.  The Kronos Early Estrogen 
Prevention Study (KEEPS; ClinicalTrials.gov Identifier: NCT00154180) looks at the 
effect of five years of treatment with cyclic micronized progesterone in combination with 
transdermal estradiol or CEE on cognitive function and cardiovascular disease in women 
aged 42 to 58 years within 36 months of their final menstrual period.  The Early Versus 
Late Intervention Trial with Estradiol (ELITE; ClinicalTrials.gov Identifier: 
NCT00114517) tests the timing hypothesis by looking at the effects of oral estradiol plus 
a vaginal progesterone gel for on cognitive function in both younger (< 6 years since 
menopause) and older postmenopausal women (10 or more years since menopause).  
Lastly, the Women’s Health Initiative Memory Study of Younger Women (WHIMS-Y; 
ClinicalTrials.gov Identifier: NCT01124773) is an ancillary study to the Women’s Health 
Initiative hormone therapy trial and assesses the impact of CEE and CEE+MPA on 
cognitive function in women who were aged 50-54 at enrollment in WHI.  The results of 
these trials will provide evidence in support or against the optimal window of opportunity 
hypothesis. 
Overall, the present findings suggest that the novel Tg rats used in these studies 
may be better models of human AD than other models currently used in the literature and 
may provide new insights into the underlying mechanisms of the disease.  The 
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development of more accurate animals models is essential to the ability to test the 
efficacy of novel therapeutics before the evaluation of therapies in human clinical trials.  
The vast number of human clinical trial outcomes that do not align with animal findings 
underscore the importance of developing accurate animal models for AD.  Despite 
promising results in animal models, there has been a failure of phase III trials of anti-Aβ 
therapies (Drachman, 2014), such as Aβ immunization with AN1792 or bapineuzumab 
and treatment with gamma-secretase inhibitor, semagacestat.  The semagacestat trial was 
terminated because participants in the active treatment arm were found to have poorer 
cognitive outcomes (Doody et al., 2013) and the bapineuzumab trial found no 
improvement in clinical outcomes in patients with AD (Salloway et al., 2014).  
Additionally, the AN1792 trial was halted when some participants developed 
autoimmune encephalopathy and there was no treatment effect on disease progression 
(Gilman et al., 2005).  The failure of these therapies in human trials implies that a firmer 
understanding of basic mechanisms underlying the disease is needed before large scale 
clinical trials are devised.  A better understanding of the disease and its progression can 
be gained from the use of animal models that better mimic the human disease.  Moreover, 
testing new therapies in more accurate animal models prior to the initiation of human 
clinical trials can help save not only substantial amounts of time and resources, but also 
human lives. 
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